AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05497453
Drug: Checkpoint Inhibitor, Immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monoclonal antibody that binds to PD-1 or PD-L1
Trial: NCT05820191
Drug: Amyvid, Intravenous Solution
RxNorm normalized name: Amyvid, intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
Trial: NCT05152498
Drug: Fu Zheng Jie Du Hua Yu therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
Trial: NCT05959720
Drug: Intrathecal Suspension
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
Trial: NCT05959720
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 D36 and D64
Trial: NCT05959720
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 D36 to D63 and D1 to D56 of consolidation
Trial: NCT05959720
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.000 mg/m2 D8, D22, D36 and D50
Trial: NCT05959720
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 D1 and D22
Trial: NCT05046561
Drug: STRI Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
Trial: NCT05046561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT06210217
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
Trial: NCT06204640
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
Trial: NCT06214273
Drug: Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anti-inflammatory, topical analgesic and topical antifungal
Trial: NCT04217304
Drug: Definity® with High Mechanical Index Ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
Trial: NCT06208280
Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
Trial: NCT04924881
Drug: COVID Rehab Formula granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID Rehab Formula granules once daily for 8 weeks
Trial: NCT06246461
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
Trial: NCT04978298
Drug: Rasigiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasigiline
Trial: NCT00002013
Drug: AS-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05052801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05179356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00915616
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05703009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06059144
Drug: Peripheral intravenous norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
Trial: NCT06386783
Drug: Fentanyl HCl
RxNorm normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
Trial: NCT05463484
Drug: Test composition Saliactive® (olive product, betaine and xylitol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated toothpaste with Saliactive®.
Trial: NCT05463484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated toothpaste without Saliactive®.
Trial: NCT05569278
Drug: GE200486 0.5M Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
Trial: NCT05493800
Drug: MIT-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr
Trial: NCT05493800
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline IV injection
Trial: NCT05629260
Drug: Post-transplantation cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
Trial: NCT04746495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
Trial: NCT04746495
Drug: Eplerenone 50mg
RxNorm normalized name: EPLERENONE 50MG TAB
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
Trial: NCT05868707
Drug: Salvage chemotherapy or best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
Trial: NCT05240391
Drug: Human Albumin 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
Trial: NCT05341141
Drug: ddEC-ddT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
Trial: NCT04433988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05653856
Drug: 64Cu-PSMA I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled Receptor-Targeted Diagnostic Product
Trial: NCT05864534
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
Trial: NCT04857632
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 20mg per day for 7 days
Trial: NCT05682196
Drug: standard of care treatment alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment alone
Trial: NCT05632562
Drug: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
Trial: NCT04793958
Drug: mFOLFOX6 Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fluorouracil~* Oxaliplatin~* Folinic acid
Trial: NCT04793958
Drug: FOLFIRI Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fluorouracil~* Irinotecan~* Folinic acid
Trial: NCT04306510
Drug: Blood samples for immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
Trial: NCT06555952
Drug: MegaNatural-BP SR 150Mg Tablet
RxNorm normalized name: MegaNatural-BP SR 150mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSE MegaNatural BP
Trial: NCT05021861
Drug: Cyproterone Acetate, Ethinyl Estradiol Drug Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
Trial: NCT05887492
Drug: TNG260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoREST inhibitor, administered orally
Trial: NCT05147259
Drug: HR011408 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
Trial: NCT06564961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab once daily
Trial: NCT06057467
Drug: Anticoagulation Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
Trial: NCT06055452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant in the placebo group takes matching placebo.
Trial: NCT05979389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
Trial: NCT04870203
Drug: anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history
Trial: NCT04870203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg every 2 weeks during 6 months only during Period A
Trial: NCT04931654
Drug: AZD7789
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Trial: NCT04722627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel Assignment
Trial: NCT04800172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo tablet once daily for 3 months.
Trial: NCT05866614
Drug: Remsima IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with Remsima IV as per the SmPC or
Trial: NCT05773170
Drug: Refralon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
Trial: NCT05719701
Drug: ICP-490
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several dose groups of ICP-490 are planned for the dose exploration.
Trial: NCT06521931
Drug: PN20
RxNorm normalized name: Lipram-PN20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
Trial: NCT06287099
Drug: BRL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single infusion of BRL-101.
Trial: NCT05562219
Drug: QA108 granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take the medication as required for 24 weeks
Trial: NCT05562219
Drug: QA108 granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take the medication as required for 24 weeks
Trial: NCT00306826
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00306826
Drug: pioglitazone + simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05029778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive placebo 3g PO, for 24 h, until birth.
Trial: NCT05641259
Drug: LP-108
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 21 or 28 days on a 28-day cycle
Trial: NCT00261820
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05004727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
Trial: NCT06442111
Drug: The placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
Trial: NCT05133310
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
Trial: NCT04587427
Drug: Radium 223 dichloride (Xofigo, BAY88-8223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed by physicians.
Trial: NCT00992472
Drug: Compazine® suppositories, 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05541107
Drug: MAT2203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral lipid nanocrystal amphotericin B
Trial: NCT05548270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Trial: NCT05263778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo by mouth once daily for 12 weeks
Trial: NCT06455670
Drug: Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
Trial: NCT05605886
Drug: Solvazinc 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
Trial: NCT05605886
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00089869
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04600323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
Trial: NCT04609670
Drug: [14C]-ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
Trial: NCT05785442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
Trial: NCT05654519
Drug: PENG/LFCN and QL Blocks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% injection
Trial: NCT05992922
Drug: IC265 Ophthalmic Solution 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop will be instilled in each eye twice a day
Trial: NCT05992922
Drug: Placebo Ophthalmic Solution (Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop will be instilled in each eye twice a day
Trial: NCT05273671
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive with a saline solution 10 min before the end of surgery
Trial: NCT06722950
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Trial: NCT06722950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo：3 times a day (daily), taken with boiled water.
Trial: NCT06722963
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
Trial: NCT05147090
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to empagliflozin 10mg daily
Trial: NCT05912192
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
Trial: NCT06050824
Drug: Comparing Load and Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin - Omeprazole - nitazoxanide - doxycycline
Trial: NCT05828485
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
Trial: NCT06266832
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, po, bid, d1-14, Q3W
Trial: NCT06411314
Drug: Pimafucin® (natamycin) 100 mg vaginal suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 suppository once daily at bedtime for 6 days
Trial: NCT05349071
Drug: physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
Trial: NCT06240728
Drug: NPX887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
Trial: NCT06466395
Drug: Hyper-CVAD
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05245968
Drug: Pimitespib
RxNorm normalized name: pimitespib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
Trial: NCT05666765
Drug: Isotretinoin ,silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.